The assessment of inflammatory activity in intestinal disease in man can be
done using a variety of different techniques. These range from the use of
non - invasive acute phase inflammatory markers measured in plasma such as
C reactive protein ( CRP) and the erythrocyte sedimentation rate (ESR) (bot
h of which give an indirect assessment of disease activity) to the direct a
ssessment of disease activity by intestinal biopsy performed during endosco
py in association with endoscopic scoring systems. Both radiology and endos
copy are conventional for the diagnosis of inflammatory bowel disease (IBD)
. However these techniques have severe limitations when it comes to assessi
ng functional components of the disease such as activity and prognosis. Her
e we briefly review the value of two emerging intestinal function tests. In
testinal permeability, although ideally suited for diagnostic screening for
small bowel Crohn's disease, appears to give reliable predictive data for
imminent relapse of small bowel Crohn's disease and it can be used to asses
s responses to treatment. More significantly it Is now clear that single st
ool assay of neutrophil specific proteins (calprotectin, lactoferrin) give
the same quantitative data an intestinal inflammation as the 4 - day faecal
excretion of 111Indium labelled white cells. Faecal calprotectin is shown
to be increased in over 95% of patients with IBD and correlates with clinic
al disease activity. It reliably differentiates between patients with IBD a
nd irritable bowel syndrome. More importantly, at a given faecal calprotect
in concentration in patients with quiescent IBD, the test has a specificity
and sensitivity in excess of 85% in predicting clinical relapse of disease
. This suggests that relapse of IBD is closely related to the degree of int
estinal inflammation and suggests that targeted treatment at an asymptomati
c stage of the disease may be indicated.